MIPSS Plus

Loading...

References

  1. Damien Luque Paz. Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.. Blood advances, 2025
  2. Matteo Guerra. Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM. American Journal of Hematology, 2024
  3. G. G. Loscocco. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation‐enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. American Journal of Hematology, 2023
  4. N. Kröger. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.. The Lancet. Haematology, 2023
  5. N. Kröger. How I treat transplant-eligible patients with myelofibrosis.. Blood, 2023
  6. H. Ali. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen.. Blood advances, 2019
  7. P. Guglielmelli. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017
  8. N M Kröger. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group.. Leukemia, 2015
  9. F. Passamonti. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).. Blood, 2010
  10. Kebede Hussein. International Prognostic Scoring System-independent cytogenetic risk categorization in primary myelofibrosis.. Blood, 2010